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Open access under CC BY-NC-ND license.SUMMARYMicroRNA deregulation is frequent in human colorectal cancers (CRCs), but little is known as to whether
it represents a bystander event or actually drives tumor progression in vivo. We show that miR-135b
overexpression is triggered in mice and humans by APC loss, PTEN/PI3K pathway deregulation, and SRC
overexpression and promotes tumor transformation and progression. We show that miR-135b upregulation
is common in sporadic and inflammatory bowel disease-associated human CRCs and correlates with tumor
stage and poor clinical outcome. Inhibition ofmiR-135b in CRCmousemodels reduces tumor growth by con-
trolling genes involved in proliferation, invasion, and apoptosis. We identify miR-135b as a key downsteam
effector of oncogenic pathways and a potential target for CRC treatment.INTRODUCTION
Colorectal cancer (CRC) arises through the progressive accumu-
lation of mutations in oncogenes and tumor-suppressor genesSignificance
Precision medicine relies on the ability to track cancer-related
drug resistance and increase therapeutic potential. We show th
carcinoma sequence converge and synergize in promoting the
anisms in mice and humans. In turn, miR-135b acts as one of th
use of anti-miR-135b in CRC mouse models has a significant
molecule downstream of oncogenic pathways involved in CRC
biomarker and a promising target for therapy.(Sjo¨blom et al., 2006). Targeting driver pathways represents the
best option to tailor cancer treatment and improve survival in pa-
tients with metastatic cancer (De Roock et al., 2011; Catenacci
et al., 2011). Although there has been recent breakthroughs inpathways and target their downstream effectors to minimize
atmutations frequently occurring in the colorectal adenoma-
progressive accumulation of miR-135b by conserved mech-
e driving forces promoting cancer phenotype. We prove that
therapeutic potential. Our results define miR-135b as a key
progression, providing the rationale for its use as a robust
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miR-135b as a Therapeutic Target in Colon Cancertargeted therapy (e.g., BRAF inhibition), this approach has two
maindisadvantages: (1) resistance frequently occurs as the result
of the activation of collateral pathways circumventing therapeutic
blockage (Prahallad et al., 2012), and (2) re-expression of lost
tumor-suppressor genes such as Adenomatous Polyposis Coli
(APC) is challenging to translate into drug development.
MicroRNAs (miRs) are a class of small noncoding RNAs
involved in cell homeostasis and carcinogenesis (Croce 2009).
Several miRs are aberrantly expressed in CRC, and their dereg-
ulation is linked to cancer progression and clinical outcome
(Valeri et al., 2009). Different oncogenic pathways can converge
to affect the same miR and in turn a single miR can control an
entire posttranscriptional program affecting dozens of target
genes. Because miRs often act as downstream effectors of pro-
tein kinases or driver genes mutated in cancer (Croce 2009), tar-
geting miRs may represent a strategy to increase specificity and
overcome drug resistance. Preliminary data on the efficacy of
miR inhibition are available and prompt the use of anti-miR tech-
nology in CRC treatment in vivo (Kasinski and Slack, 2011).
RESULTS
Identification of miRs Dysregulated in CRC Mouse
Models
To define miRs deregulated in relation to CRC-specific path-
ways, we performed a genomewide miR profiling on matched
tumor and normal tissues from six mice from two different
CRC mouse models: the CDX2P-NLS Cre;Apc+/loxP (CPC;Apc)
model harbors a truncating mutation affecting one APC allele
(Hinoi et al., 2007). In the azoxymethane (AOM)/dextran sulfate
sodium (DSS) model (Grivennikov et al., 2009), mice develop
CRC as the result of the mutations in several genes including
phosphoinositide 3-kinase (Pi3K), V-Ki-ras2 Kirsten rat sarcoma
viral oncogene homolog (K-ras), Catenin (Cadherine Associ-
ated-protein) Beta 1 (Ctnnb1) and Proto-oncogene tyrosine-
protein kinase Src (Src) pathways (Chen and Huang 2009)
Thirty-five miRs were aberrantly expressed in polyps from the
CPC;Apc model with p < 0.001, with seven miRs increased and
14 decreased by greater than 2-fold. In the AOM/DSS model; 57
miRs were aberrantly expressed in tumor compared to normal
tissues with p < 0.001; among these, 13 miRs increased and
nine decreased by greater than 2-fold (Figure 1A; Tables S1
and S2 available online). We focused on overexpressed miRs
because these may be easier to harness as prognostic bio-
markers (Croce 2009) or as therapeutic targets compared to
downregulated ones (Kasinski and Slack, 2011). MiR-135b was
the most overexpressed miR in both models (Figure 1A). RT-
PCR and in situ hybridization (ISH) confirmed miR-135b overex-
pression in tumor tissues (Figures 1B and 1C).
MiR-135b Is Overexpressed in Human CRC
We analyzed 454 sporadic and 31 inflammatory bowel disease
(IBD)-associated CRCs to confirm miR-135b upregulation previ-
ously reported in smaller CRC cohorts (Necela et al., 2011; Nagel
et al., 2008; Gaedcke et al., 2012). A first set including 62 spo-
radic CRCs was analyzed for miR-135b expression by RT-
PCR. MiR-135b expression showed an average 4-fold change
in cancer compared to paired normal tissue and correlated
with tumor progression as it was increased in the sequence470 Cancer Cell 25, 469–483, April 14, 2014 ª2014 Elsevier Inc.from stage I to stage IV CRC (Figure 1D, upper). Re-analysis of
392 tumor samples for which tumor stage andmiR-135b expres-
sion were available from themiR-seq data set of the CRCCancer
Genome Atlas (The Cancer Genome Atlas Network, 2012; Fig-
ure 1D) confirmed thatmiR-135b upregulation follows tumor pro-
gression. Paired analysis of matched normal and cancer tissues
from the same cohort also showed that miR-135b reads are
virtually absent in normal tissues (Table S3), suggesting that
miR-135b is a CRC specific deregulated miR; thus, a valuable
biomarker and target for therapy.
For IBD-associated CRCs, three different cohorts were
analyzed: miR-135b was upregulated by > 7.0-fold in cancer
compared to normal tissues in all the different sets. Interestingly,
135b overexpression was found in dysplasia compared to
normal tissues, suggesting it might be an early event in colon
carcinogenesis (Figure 1D, lower). ISH showed that miR-135b
is strongly expressed in the cytoplasm of dysplastic and cancer
cells whereas, in line with the TCGA data, little signal is observed
in normal mucosa (Figure 1E).
Tumor stage and nodal status were confirmed as prognostic
markers in our cohort of sporadic CRC (Figure S1). To test if
miR-135b is associated with clinical outcome in CRC, patients
were stratified according to the logarithmic ratio between
miR-135b expression in cancer and normal tissues: high if log2
miR-135bexpressionwas>2 (above the averagemiR-135bover-
expression observed in Figure 1D), and low if log2 miR-135b
expression was%2. High miR-135b expression was associated
with poor overall survival and relapse-free survival (Figure 1F). A
subgroup analysis in patients with stage II CRC identified a trend
toward a worse prognosis for patients with highmiR-135b. How-
ever, the difference was not statistically significant (p = 0.055),
likely due to the small sample size (Figure 1F).
MiR-135b Overexpression Is Associated with Mutations
in Specific CRC Pathways
Loss of Apc is the initiatingmutation in the CPC;Apcmodel (Hinoi
et al., 2007). To confirm that miR-135b overexpression is due to
APC loss, we re-induced APC by transfecting a plasmid encod-
ing the APC full coding sequence (CDS) in the SW480 human
CRC cells, which only contains a mutated APC allele leading to
a truncated protein (Qian et al., 2008) . Re-expression of wild-
type (WT) APC caused a 65% reduction in miR-135b expression
(p = 0.03), whereas inhibition ofAPC by siRNA resulted in a 5-fold
increase (p = 0.01) in miR-135b expression in normal colon
epithelial cell lines (Moyer et al., 1996; Figures 2A, 2B, and
S2A–S2C) Inactivating mutations in APC cause stabilization
and nuclear translocation of b-catenin with induction of a com-
plex transcriptional program. To test whether APC loss results
in miR-135b overexpression through b-catenin stabilization, we
increased b-catenin expression either by transfecting NCM 460
cells with a plasmid encoding the b-catenin transcript or by sta-
bilizing b-catenin with lithium chloride (LiCl) treatment. Both ex-
periments resulted in increasedmiR-135b expression (3-fold [p =
0.003] and 4.6-fold [p = 0.007], respectively; Figures 2C and
S2D). An siRNA screen against the major transcription factors
involved in the APC/b-catenin axis was run on two cell lines
with high basal b-catenin activity, HCT-116 (b-catenin mutant;
Ilyas et al., 1997) and SW480 (APC null cells; Qian et al., 2008),
revealing that TCF4 and LEF1 silencing causes miR-135b
Figure 1. MiR-135b Upregulation in Mouse and Human CRC
(A) Genome-widemiR expression analysis in tumor and normal adjacent colon tissues fromCPC;Apc and AOM/DSS treatedmice. Selected deregulated miRNAs
in cancer relative to normal tissues are plotted against the p value.
(B and C) MiR-135b expression by RT-PCR (B) and ISH (C) in both CRC mouse models. Scale bars, 200 um (100 um in the magnification).
(D) MiR-135b expression was assessed in human tissues. Paired analysis (a) and miR expression according to stage (b) in sporadic CRC (n = 62) are shown.
Reads for miR-135b from the TCGA miR-seq data set (n = 392) are shown (c). miR-135b upregulation in three different cohorts of IBD-associated CRC (n = 31):
OSU (n = 9; d), University of Ferrara (n = 9; e), and University of Padua (n = 13; f).
(E) ISH for miR-135b in human cancer and normal epithelial cells. Scale bars, 200 um (50 um in the magnification).
(F) Prognosis of sporadic CRC patients according to miR-135b expression: (a) overall survival (OS) in the entire cohort, (b) relapse-free survival (RFS) in stage
I-II-III CRC, (c) RFS in stage II-III only CRC and (d) in stage II only CRC. High or low miR-135b expression was defined as low if Log2-miR-135b-ratio (cancer/
normal)%2 or high if Log2-miR-135b-ratio > 2.
See also Tables S1–S3 and Figure S1.
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Figure 2. MiR-135b Overexpression Is Associated with Mutations in Specific CRC Pathways
(A) miR-135b expression following transfection with a plasmid encoding the APC CDS in APC mutant SW480 cells.
(B) miR-135b expression following APC silencing in normal colon (NCM 460) epithelial cells.
(C) miR-135b expression (left) following overexpression of CTNNB1 (right) in NCM 460 normal epithelial cells.
(D) miR-135b expression following silencing of TCF4 and LEF1 transcription in APC mutant SW480 cells (left) or CTNNB1 mutant HCT-116 cells (right).
(E–G) miR-135b expression in MEFs (E), human normal and CRC cell lines (F), and tumor-derived organoids from GEMMs (G) harboring different rounds of
mutations in genes commonly mutated in human CRC.
(H–J) miR-135b expression in PI3KCA WT and mutant HCT-116 cells after serum starvation (H), treatment with LY-294002 (I), and transfection with specific
siRNAs to FoxO1 and FoxO3A (J).
(K) miR-135b expression in parental SW480 and SW620 CRC cell lines after treatment with dasatinib.
(L) miR-135b expression in Src-MEFs after treatment with PI3K or MEK1/2 inhibitors.
(M) miR-135b expression in tumor derived from AhCre Apcfl/flSrc+/+ and AhCre Apcfl/flSrcfl/fl mice.
(legend continued on next page)
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miR-135b as a Therapeutic Target in Colon Cancerinhibition (Figures 2D and S2E) . Taken together, these data sug-
gest that miR-135b can be activated by the APC/b-catenin/
TCF4-LEF1 pathway.
To study other pathways involved inmiR-135b overexpression
that may account for the higher expression of miR-135b in AOM/
DSS compared to CPC;Apc tumors, we screened miR-135b
expression in a series of mouse embryonic fibroblasts (MEFs)
engineered to harbor mutations in specific oncogenes and in hu-
man CRC cell lines (Figures 2E and 2F). The analysis revealed
increased levels of miR-135b (5-fold change; p < 0.001) in cells
expressing the H1047R mutant of PIK3CA, which encodes the
a isoform of the catalytic subunit of PI3K. Expression of the d iso-
form of Pi3k and of Src also led to increased levels of miR-135b
(7.5 and 9.7, respectively; p < 0.001), whereas viral Jun did
not affect the expression of miR-135b (Figure 2E). The effect
of PI3K and Src on miR-135b was correlated with their onco-
genic potency in 10T1/2 mouse fibroblasts. The cells overex-
pressing these proteins are morphologically transformed
and capable of anchorage-independent growth (Hart et al.,
2011). In contrast, the cells expressing v-Jun show fibroblastic
morphology, with only a minority of cells producing colonies in
agar suspension.
In human CRC cells, miR-135b expression follows the accu-
mulation of mutation in APC, PI3KCA, and SRC (Figure 2F).
RKO cells lack mutations in APC/b-catenin, show low basal
SRC activity, and harbor an H1047R mutation in PIK3CA and
are characterized by low miR-135b basal expression. HCT-116
cells are characterized by b-catenin activating mutations,
PI3KCA mutations, and moderate SRC activity and display
increased miR-135b expression. Parental SW480 cells and their
metastatic derivative SW620 have the same mutations in APC,
and no mutations in PI3KCA, but have different SRC activity
and show highmiR-135b expression (daCosta et al., 1999; Sam-
uels et al., 2005; Dehm et al., 2001).
To study the effect of collateral pathways frequently mutated
in CRC, we tested miR-135b expression in tumor-derived orga-
noids fromCRC genetically engineered mousemodels (GEMMs)
that underwent different rounds of knock-in or knock-out muta-
tions in Apc, Kras, the Phosphatase and Tensin homolog deleted
on chromosome TEN (Pten), and p53 (Figure 2G). In keeping with
our initial findings, Apc loss was associated with miR-135b upre-
gulation in comparison to normal controls. Pten is a negative
regulator of the PI3K pathway and these genes are mutually
lost in breast and CRC cancer (Frattini et al., 2005), thus we
decided to use Ptenfl/fl mice as a model to study PI3K activation
in CRC (Marsh et al., 2008). Consistent with our in vitro data,
simultaneous loss of Apc and Pten caused further upregulation
in miR-135b compared to Apcfl/fl organoids. In contrast,
KrasG12-activating mutations did not affect miR-135b expres-
sion. Apcfl/fl /Ptenfl/fl /KrasG12 triple mutant organoids showed
miR-135b deregulation similar to that of the Apcfl/fl /Ptenfl/fl or-
ganoids supporting the hypothesis that the PI3K/PTEN pathway
exerts a critical role in controlling miR-135b expression. Finally,(N) Luciferase reporter assay was performed after LiCl treatment using differen
135b;1 position corresponds to the 50 terminus of the miR-135b hairpin. Putativ
the miR-135b sequence is in red. Deletion of the TCF4 binding site is represente
Human or mousemiR-135b expression was assessed by RT-PCR and normalized
three experiments; p values are reported within the figures. See also Figure S2.loss of p53 caused a 10-fold change in miR-135b compared to
Apcfl/fl organoids.
To study the role of PI3K in the modulation of miR-135b, we
used human CRC cell lines (HCT-116, H1047R and DLD-1, and
E545K) in which either the PI3KCA mutant or WT allele was dis-
rupted (Samuels et al., 2005). PIK3CAmutations have little effect
on cancer phenotype under basal conditions, but they cause
reduced cellular dependence on growth factors affecting cell
growth and apoptosis in serum starvation. MiR-135b expression
is increased in PI3KCA mutant compared to WT cells (less than
2-fold change) in basal conditions. Serum starvation forced the
PI3KCA mutation phenotype, increasing the difference in miR-
135b expression (3.7 and 4.3 fold change; p < 0.001 in
HCT116 and DLD-1, respectively; Figures 2H and S2F). These
experiments suggest that miR-135b is dependent upon PI3K
activation. We treated HCT-116 cells with the PI3KCA inhibitor
LY294002 after starvation and observed marginal effects on
WT cells, but reduction (65%; p < 0.001) of miR-135b in mutant
cells (Figure 2I). The transcription factors FoxO1 and FoxO3A
promote the PI3K cancer-associated phenotype in these cell
lines (Samuels et al., 2005). To investigate whether miR-135b
is under the control of the FoxO transcription factors family, we
silenced FoxO1 and FoxO3A with siRNA in HCT-116 PI3KCA
WT cells and observed an increase in miR-135b expression.
Silencing FoxO1 and 3A inWT cells increasedmiR-135b to levels
similar to those observed in PI3K mutant cells (Figure 2J). In
conclusion, PI3KCA mutations may induce miR-135b by phos-
phorylating and inactivating FoxO1 and FoxO3A or altering
FoxO1/3A targets.
SRC is nonmembrane receptor tyrosine kinase (Yeatman
2004) and induces activation of several pathways. MiR-135b
was overexpressed in v-Src expressing MEFs compared to WT
cells (Figure 2E). Dasatinb, a SRC inhibitor (Serrels et al.,
2006), reduced the expression of miR-135b in SW620 CRC cells
to levels observed in their parental nonmetastatic counterpart
(SW480; Figure 2K). Because SRC can activate a plethora of
downstream effectors, we focused only on those previously
analyzed in our MEF screening: PI3K and MAPK. Our data sug-
gested that the MAPK pathway is not responsible for miR-135b
overexpression because overexpression of v-Jun (Shaulian
2010) showed no effect on miR-135b expression. LY294002
reduced the expression of miR-135b by 40% (p = 0.03) in
v-Src expressing MEFs, whereas a MEK1-2 (Yoon et al., 2011)
inhibitor did not affect miR-135b expression (Figure 2L). Loss
of Src attenuates the intestinal phenotype caused by Apc loss
both in flies and mice (J.C. and O.J.S., unpublished data). Inter-
estingly, in our system, loss of Src in AhCRE Apcfl/fl mice was
associated with a reduction in miR-135b expression (Figure 2M).
These observations suggested that, at least in part, SRC induces
miR-135b overexpression through the PI3K/AKT/FoxO pathway.
However, we cannot rule out the possibility that other SRC effec-
tors contribute to miR-135b overexpression. This hypothesis is
supported by the observation that PI3K inhibition only partiallyt vectors containing predicted TCF4 binding sites upstream of the pre–miR-
e TCF4 responsive sequences (CTTTGTT)) are indicated in the gray boxes, and
d by a X.
to that of RNU48 or SNU234, respectively. Bars represent the mean and SD of
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that STAT3 can induce miR-135b overexpression in large cell
lymphomas (Matsuyama et al., 2011).
MiR-135b is located on the negative strand of 1q32.1 and
overlaps with exon 1 of the LEM domain-containing 1 (LEMD1)
gene (Figure S2G). LEMD1 is overexpressed in prostate cancer
(Ghafouri-Fard et al., 2010) and anaplastic cell lymphoma (Mat-
suyama et al., 2011). Gene expression analysis suggests that
only a (657 nt) LEMD1 isoform is expressed in CRC (Yuki et al.,
2004).
To test whether miR-135b transcription is depended upon
LEMD1 activation, we analyzed the expression of LEMD1 and
miR-135b following inhibition of transcription factors involved
in miR-135b expression (Figure S2H). RT-PCR using LEMD1
primers covering all the different spliced LEMD1 isoforms
revealed no change in LEMD1 expression in relation to TCF4/
LEF1 silencing suggesting that miR-135b activation is indepen-
dent from LEMD1 in CRC. Because the loss of APC and the acti-
vation of the b-catenin/TCF4 pathway seem to be the initiating
event in miR-135b deregulation, we subcloned the 2.5 kb
area up-stream of the 50 terminus of miR-135b hairpin into the
pGL3 reporter vector (PGL3-miR-135b-P1 for the full-length,
WT plasmid) and we tested luciferase activity following LiCl stim-
ulation (Figure 2N). Two putative TCF4 binding sites (distal and
proximal to the 135b hairpin) were identified in this area (http://
genome-euro.ucsc.edu; Figure 2N). Subcloning of the two pre-
dicted binding sites and mutagenesis experiments allowed to
define the distal binding site as the one involved in miR-135b
activation (PGL3-miR-135b-P2/P5 M1-M2; Figure 2N).
We previously showed that FoxO transcription factors exert a
negative control on miR-135b activation (Figure 2J). To test
whether FoxO binds to miR-135b promoter, we looked for
potential FoxO consensus sequences and we identified a
conserved area located 300 bp (289 to 280) upstream of the
hairpin precursor. When NCM460 cells were cotransfected
with siRNA to FoxO3a or FoxO1 and the PGL3-miR-135b-P1
plasmid, no effect was seen on promoter activation (data not
shown), suggesting that FoxOs do not have a direct interaction
with miR-135b promoter. Because FoxOs can bind b-catenin
preventing the activation of TCF4 (Hoogeboom et al., 2008),
we tested whether modulation of Foxo3a would cause any
change to promoter activation induced by b-catenin stabiliza-
tion. Interestingly, silencing of Foxo3a increased miR-135b pro-
moter activation (1.9-fold change; p = 0.004), whereas FoxO
overexpression reduced (63% reduction; p = 0.003) the lucif-
erase activity (Figure S2I, blue bars). A TOPFLASH plasmid con-
taining multiple copies of an optimal TCF-binding site and a
FOPFLASH plasmid containing multiple copies of a mutant
form of a TCF-binding site were used in parallel to confirm
TCF4 inhibition by FoxO (Figure S2I, red bars). These data under-
pin the synergic activity of the PI3K and APC pathways in con-
trolling miR-135b activation, proving that different oncogenic
pathways merge on miR-135b activation directly and indirectly.
MiR-135b Affects Apoptosis and Cell Growth
APC/Wnt/b-catenin signaling is pivotal for cell division and is
linked to reduced apoptosis (Morin et al., 1996; Groden et al.,
1995). To test the contribution of miR-135b on APC/b-catenin-
mediated apoptosis, we cotransfected SW480 cells with a474 Cancer Cell 25, 469–483, April 14, 2014 ª2014 Elsevier Inc.plasmid encoding the full APC CDS (APC-EGFP) or an empty
vector (empty EGFP) in combinations with LNA-anti-miR-135b,
pre-miR-135b or controls. In line with previous evidence (Morin
et al., 1996; Groden et al., 1995), APC re-expression caused
apoptosis (Figure 3A). Similarly, the inhibition of miR-135b alone
induced apoptosis. The cotransfection of miR-135b and APC-
EGFP rescued the effect on apoptosis due to the re-induction
of APC (Figure 3A). APC is a target of miR-135b (Nagel et al.,
2008); however, in our experiments the APC-EGFP vector con-
tains only the APC CDS and not the 30UTR. These data suggest
that re-expression of APC causes apoptosis, at least in part, by
downregulating miR-135b.
To test the effects of miR-135b on cell growth, we used HCT-
116PI3KCAWTandmutant cells (Samuels et al., 2005).PI3KWT
cells overexpressing miR-135b showed increased proliferation
after 48 hr, and the difference was still statistically significant
after 5 days. Similarly, PI3KCA mutant cells transfected with
anti-miR-135b showed reduced proliferation compared to the
LNA-control cells (Figures 3B, S3A, and S3B; Tables S4 and
S5). The presence of PI3KCA mutations also affected growth in
soft agar. Silencing of miR-135b reduced the number of colonies
in the PI3KCA mutant cells, whereas miR-135b overexpression
resulted in increased colony formation (Figures 3C and S3C).
Moreover, inhibition of miR-135b in SRC-MEFs inhibited their
ability to form colonies in soft agar. Anti-miR-135b or scramble
lenti-viral vectors were used to infect SRC-MEFs (Figure 3D).
MiR-135b repression caused a 95% reduction (p < 0.001) in
the number of colonies in SRC-transformed MEFs (Figures 3E
and 3F), supporting the hypothesis that miR-135b is a major
driver of SRC-induced transformation.
Targeting miR-135b Affects Tumor Growth In Vivo
Apc loss causes alterations in the crypt-villus architecture pro-
moting classical features of neoplastic transformation such as
increased proliferation and loss of differentiation. To investigate
the role ofmiR-135b in Apc loss-mediated transformation in vivo,
we designed specific oligonucleotides to target endogenous
miR-135b (anti-miR-135b oligonucleotides [miR-135b-AMO]
and scrambled-oligonucleotides [Scramble-AMO]). The miR-
135b-AMO silencing efficacy was initially tested in vitro and
in vivo (Figures S4A and S4B). A custom probe recognizing
the-miR-135b-AMO oligonucleotides was used for ISH and re-
vealed a strong signal in colon epithelium, suggesting that the
miR-135b-AMO was taken up and retained in mice intestine for
at least 48 hr following injection (Figure S4B). Off-target effects
of miR-135b-AMO on other miRs were excluded (Figure S4C).
To study the contribution of miR-135b to the phenotype
induced by APC loss, we triggered rapid Apc inactivation by
the administration of b-napthoflavone to AhCre+Apcfl/fl mice as
previously described (Sansom et al., 2004). MiR-135b-AMO
and Scrambled-AMO were given intraperitoneally at a dose of
50 mg/kg on days 2 and 4 and mice were euthanized on day 4
(Figure 4A). Apc inactivation was associated with b-catenin
activation and nuclear localization in both treatment groups
(Figure S4D). Apc loss caused a 10-fold increase in miR-135b
expression in Cre+Apcfl/fl compared to Cre+Apc+/+ controls
(WT hereafter) definitively showing that mir135b is directly
activated following Apc loss. MiR-135b-AMO caused a marked
reduction in miR-135b expression (70%; p < 0.001) in the
Figure 3. MiR-135b Mediates the Cancer
Phenotype Induced by APC and PI3KCA
Mutations
(A) APC mutant SW480 cells were transfected with
pre-miR-135b, LNA anti-miR-135b, or controls in
combination with a plasmid encoding the APC CDS
or an empty vector. Apoptotic cells were measured
by flow cytometer (left) and quantitated (right).
(B) Isogenic PI3KCA WT and mutant HCT-116
cells were transfected with pre-miR-135b, LNA anti-
miR-135b, or relative controls. Cell viability was
measured at selected time points.
(C) Isogenic PI3KCA mutant and WT HCT-116 cells
overexpressing miR-135b or anti-miR-135b were
plated in soft agar and grown in low fetal bovine
serum conditions. Colonies greater than 2 mm in
size were counted and quantitated. Representative
images are shown.
(D–F) v-SRC transformed MEFs were infected
with lentiviruses encoding an anti-miR-135b or a
scramble hairpin. Cells were selected with puromy-
cin and checked for viral integration using GFP
(scale bars, 20 um; D). Cells were grown in soft agar
and colonies were counted after 4 weeks. On the far
left of the plate, no cells were seeded as negative
control (E). GFPwas used tomonitor viral integration
during for the entire duration of the experiment (F).
Scale bars, 200 um (week 1) and 400 um (week 4).
Bars represent the mean and SD of three experi-
ments; p values are reported within the figures.
See also Tables S4 and S5 and Figure S3.
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compared to scrambled-AMO-treated mice (n = 6 [scrambled-
AMO mice hereafter]; Figure S4E). In the scrambled-AMO, loss
of the crypt structures and occupation of the crypt-villus axis
by atypical cells was observed; indeed, cellularity was doubled
compared to that of WT mice (89.8 ± 6 cells per crypt VS 41.6 ±
2.3 cells per crypt; p = 0.0001) and the number of mitotic figures
per crypt was increased (average 3.16 vs. 1.35; p = 0.03; FiguresCancer Cell 25, 469–4B and 4C). In the Cre+Apcfl/fl 135b-AMO,
a normal morphology was retained, cellu-
larity and number of mitosis (54.8 ± 3;
p 0.02 and 1.6 ± 0.7, respectively) were
importantly reduced compared to scram-
bled-AMO mice (Figures 4B and 4C). To
define changes in proliferation, mice from
all the three groups (n = 3) were injected
with BrdU and killed 2 hr later on day 4.
Scoring of the proportion of cells in Sphase
revealed a 43% increase in proliferation in
the scrambled-AMO mice compared to
the WT mice (BrDU-positive cells 40.5 vs.
28.4; p = 0.01). 135b-AMO mice showed
decreased proliferation compared to
scrambled-AMO (mitotic index: 27.1; p =
0.02) and no difference compared to the
WT mice (Figure 4B, right) with a clear
cleavage plain between the expected mid
crypt proliferation region and the upper
compartment (Figure 4C).Because the AOM/DSS better resembles the high level of
genetic instability observed in human CRC (The Cancer Genome
Atlas Network, 2012) compared to the CPC;Apc model, we
tested this model to study the therapeutic potential of 135b-
AMO in vivo. Colorectal carcinogenesis was induced using the
AOM/DSS protocol and 135b-AMO or scrambled-AMO were
administered simultaneously twice a week for the entire duration
of the treatment (Figure 5A). After 100 days, the mice were483, April 14, 2014 ª2014 Elsevier Inc. 475
Figure 4. miR-135b Inhibition Rescues Apc-Induced Phenotype In Vivo
(A) Conditional Apc deletion induced by b-napthoflavone injection in AhCre+Apc+/+ mice on days 1 and 3. miR-135b-AMO or scrambled-AMO were injected on
days 2 and 4. Mice (n = 6 for each group) were euthanized on day 4.
(B) Graphs show total cells per crypt (left) and proliferation index (ratio between BrDU-positive cells and total cells per crypt; right) in AhCre+Apc+/+ and
AhCre+Apcfl/flmice treatedwith scramble-AMOor anti-135b-AMO. BrDUwas injected in threemice per group 2 hr prior to euthanization. Error bars represent SD;
p values are shown within the graphs. Magnification bars, 100 um (top), 50 um (bottom).
(C) Hematoxylin and eosin (H&E) and BrDU-stained sections for AhCre+Apc+/+ and AhCre+Apcfl/fl mice treated with scramble-AMOor anti-135b-AMO. Bars show
size of the crypts. Magnification bars, 100 um (top), 50 um (bottom).
See also Figure S4.
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of the mice showed signs of toxicity related to AMO treatment or
had to be euthanized before the end of the study due to toxicity.
MiR-135b-AMO reduced the median number and the size of
tumors (Figures 5B–5D). No differences were observed be-
tween the scrambled-AMO and the control group. Microscopy
showed that MiR-135b-AMO tumors were well differentiated
with an acinar pattern, whereas tumors in the scrambled-
AMO group showed poor differentiation and an adenomatous
pattern (Figure 5C). Effective miR-135b downregulation in
135b-AMO treated mice was confirmed by RT-PCR and ISH
(Figures S5A and S5B). Proliferation was remarkably reduced
in tumors from miR135b-AMO compared to scrambled-AMO
(Ki-67 positive cells 60% vs. 35% p < 0.01; Figure 5E).
Apoptosis was analyzed by an immunofluorescence-based476 Cancer Cell 25, 469–483, April 14, 2014 ª2014 Elsevier Inc.TUNEL assay. The percentage of apoptotic cells and the
intensity of the signal were increased in the anti-miR-135b tu-
mors in comparison to the scrambled-AMO tumors (Figure 5F).
No significant differences were observed in other organs
(Figure S5C).
To dissect the contribution of miR-135b overexpression to
each single pathway, we infected CRC GEMM-derived organo-
ids with lentiviruses silencing miR-135b or controls; we xeno-
transplanted the tumors in nude mice and monitored tumor
growth (Figure 6A). Given that Apcfl/fl/Ptenfl/fl and Apcfl/fl/
KrasG12/+/P53R172H/fl-derived organoids were the two models
that showed progressive deregulation of miR-135b compared
to Apcfl/fl organoids, these were used for the experiments.
Apcfl/fl/KrasG12/+ organoids did not show any significant differ-
ence in miR-135b expression compared with Apcfl/fl and were
Figure 5. Anti-miR-135b Exerts an Antitumor Effect In Vivo in the AOM/DSS Model
(A–C) Overview of the study (A): AOMwas given once, followed by periodic administration of DSS in water. MiR-135b-AMOor scrambled-AMOwere given twice a
week for 100 days. Mice were treated with miR-135b-AMO (n = 8), scrambled-AMO (n = 8), or left untreated (n = 8). Following euthanization, macroscopic (B) and
microscopic (C) analysis of the tumors was performed. Scale bars, 200 um (top), 100 um (bottom).
(D) Statistical analysis of tumor number (multiplicity, a), tumor number for tumors >2mm (b), tumor volume (load, c), average size (d), and tumor size distribution in
the two groups (e).
(E and F) Cancer tissues from mice treated with miR-135b-AMO or scrambled-AMO were analyzed. (E) Ki-67 expression was assessed with immunohisto-
chemistry (a) and quantitated (b; scale bars, 200 um [top], 100 um [bottom]). (F) Apoptosis was assessed by immunofluorescence (scale bar, 200 um).
See also Figure S5.
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reason were not included in the study.
For each genotype, organoids were infected with lentiviral
vectors inhibiting miR-135b (anti-135b) or controls (anti-miR-scramble; Figure 6B). Mir-135b downregulation was checked
by RT-PCR following infection and puromycin selection (Fig-
ure 6C). Xenotransplanted tumors (50 organoids for eachmouse,
six mice per group) were measured twice a week for 2 months orCancer Cell 25, 469–483, April 14, 2014 ª2014 Elsevier Inc. 477
Figure 6. miR-135b Inhibition Causes Tumor Inhibition in Organoids Derived from CRC GEMMs
(A and B) Tumor-derived organoids from Apcfl/fl/Ptenfl/fl and Apcfl/fl/KrasG12/+/P53R172H/fl (A) infected with lentiviruses encoding anti-miR-135b or scramble
hairpins (B) were xenotransplanted in nude mice. Tumors were measured twice a week for 8 weeks or until ulceration.
(C) miR-135b expression was assessed by RT-PCR in tumor-derived organoids after infection. Bars represent the mean and SD of three experiments; p < 0.01.
(D) Microscopic analysis (left) and tumor growth (right) in Apcfl/fl/Ptenfl/fl organoids.
(E) Microscopic analysis (left) and tumor growth (right) in Apcfl/fl/KrasG12/+/P53R172H/fl organoids.
Results are expressed as the mean percentage of change in tumor volume for each group of mice, ± SEM. See also Figure S6 and Tables S6 and S7.
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vested and analyzed for proliferation and apoptosis. Lentiviral
integration and miR-135b downregulation were controlled by
GFP staining and RT-PCR, respectively (Figure S5).
In the Apcfl/fl/Ptenfl/fl, we observed striking differences in tu-
mor growth (Figure 6D; Table S6). Six weeks following transplan-
tation, three of six tumors regressed to the point that they could
not be detected macroscopically and the other three showed a
cessation of growth. Immunohistochemical analysis showed
that proliferation was almost entirely abolished in the miR-135b
group compared to controls (Figure 6D).
Apcfl/fl/KrasG12/+/P53R172H/fl xenografts infectedwith anti-miR-
scramble grew rapidly, and four of six tumors ulcerated after
3 weeks (Figure 6E; Table S7). In contrast, anti-135b tumors
only doubled in 3 weeks and no ulceration was observed until
week 8. Tumor growth was inhibited in the anti-135b group and
this was supported by the observation that proliferation was in-
hibited in the lenti-135b group compared to controls (Figure 6E).
MiR-135b Targets Tumor-Suppressor Genes
To find potential target genes affected by miR-135b overexpres-
sion, we performed a gene expression analysis in normal epithe-
lial colon cells overexpressingmiR-135b (Figure 7A). The analysis
of a cancer-associated gene panel revealed that 35 genes were
dysregulatedbymiR-135boverexpression (TableS8). Amatched
analysis ofmiR-135bdownregulated genes and target prediction
algorithms (Lewis et al., 2003; Rehmsmeier et al., 2004) showed
that several genes were potentially controlled by miR-135b:
transforming growth factor b receptor 2 (TGFbR2), death-associ-
ated protein kinase 1 (DAPK1), and APC. Data from the array
analysis were confirmed by RT-PCR in the same cell line and
in a second normal epithelial cell line (NCM 356; Figures 7B and
S7A). We identified predicted binding sites for miR-135b in
each of these genes (Lewis et al., 2003; Rehmsmeier et al.,
2004; Figure 7C). Luciferase experiments confirmed the speci-
ficity of the miR-135b-target interaction (Figure 7D).
DAPK1 is frequently downregulated in CRC, and promoter
methylation does not seem to be the main mechanism by which
this occurs (Xu et al., 2004; Borinstein et al., 2010). Western blot
analysis proved thatmiR-135b can affect DAPK1 protein expres-
sion (Figure 7E). Analysis of DAPK1 expression in human IBD-
associated CRC confirmed the downregulation of this gene in
cancer and dysplasia compared to normal tissues (Figure 7F).
Correlation analysis between miR-135b expression and DAPK1
mRNA showed an inverse correlation (r = 0.4, p = 0.036).
TGFbR2 downregulation is common in CRC (Biswas et al.,
2004; Guda et al., 2001) and in vitro evidence suggests that
dynamic changes in TGFbR2 expression can have an effect on
p21-mediated/TGF-b-induced apoptosis (Rojas et al., 2009) .
Stimulation of cells with TGF-b (10 nM) induced p21 activation
in scrambled transfected cells whereas miR-135b overexpres-
sion or TGFbR2 silencing caused reduced p21 activation and
reduced apoptosis (Figures 7G and 7H). These data suggest
that the miR-135b effect on apoptosis is partially mediated by
TGFbR2 downregulation. Analysis of TGFbR2 expression in
IBD-associated CRC showed TGFbR2 downregulation in cancer
compared to normal and dysplastic tissues (Figure 7I). Corre-
lation analysis between miR-135b expression and TGFbR2
mRNA showed an inverse correlation (r = 0.46, p = 0.015).Our gene expression analysis revealed that miR-135b upregu-
lation induces interleukin 8 (IL8) overexpression (Table S8;
Figures 7J and S7B). IL-8 is an important cytokine involved in
proliferation, invasion, migration, and neo-angiogenesis (Waugh
and Wilson 2008). IL-8 is frequently involved in hypoxia
response; thus, we looked at whether miR-135b could have an
effect on IL-8 through HIF1a transcriptional regulation. No
changes in HIF1a mRNA were observed following miR-135b
overexpression (fold change 1.01; p = 0.77; Table S8), suggest-
ing that IL8 overexpression was independent from HIF1a tran-
scriptional regulation. Because our experiments were performed
in condition of normoxia, we looked for a nontranscriptional
regulator of HIF1a and searched for potential miR-135b binding
sites in HIF1a regulators. FIH is an asparagine hydroxylase that
prevents HIF1a activation in normoxia (Mahon et al., 2001). Inter-
estingly FIH harbors a miR-135b binding site (Figure 7K). We
proved FIH as a target of miR-135b (Figures 7K–7M and S7C).
To support a role of miR-135b in FIH regulation in vivo, we
measured FIH mRNA expression in human IBD-associated
CRC and found the gene was downregulated in cancer
compared to normal and dysplastic tissues (Figure S7D). Corre-
lation analysis between miR-135b expression and FIH mRNA
showed an inverse correlation (r = 0.42; p = 0.02). To confirm
that miR-135b controls IL-8 production through FIH/HIF1a, we
measured IL8 and VEGFA expression after miR-135b manipula-
tion (Figures 7N and S7E). MiR-135b promoted IL-8 and VEGFA
overexpression and a similar effect was caused by FIH silencing
or by hypoxia. Interestingly HIF1a siRNAs were able to rescue
the effect on IL-8 and VEGFA by miR-135b. These observations
suggested that miR-135b was acting on both cytokines through
a FIH/HIF1a axis (Figure 7N). To test if the increase in IL-8
induced by miR-135b was relevant in promoting a functional
effect on neo-angiogenesis, the supernatant from miR-135b
overexpressing cells was used for a neo-angiogenesis assay.
HUVEC grown with media from miR-135b transfected cells
showed a 3-fold change increase in their ability to form tubes
compared to those cultured with media from scrambled trans-
fected cells (Figure 7O).
DISCUSSION
Using in vitro and in vivo models, we define the genetic events
driving miR-135b deregulation in CRC. Our observations explain
why miR-135b upregulation is consistently observed in human
and mouse CRC (Nagel et al., 2008; Gaedcke et al., 2012), mak-
ing this miR a robust and reproducible biomarker. Our findings
complement those of a recent report that identifies miR-135b
as one of the most upregulated miRs in Apcmin/+ mice (Necela
et al., 2011), suggesting that miR-135b deregulation is indepen-
dent of the specific Apc mutation or site of inactivation. Data
from mouse tumors and human dysplastic tissues suggest that
miR-135b upregulation is an early event in tumor transformation
as supported by the observation that miR-135b is directly linked
to rapid Apc loss in the AhCreApcfl/flmodel and inhibition of miR-
135b rescues the phenotype induced by Apc loss in a way that
resembles c-Myc deletion in mice intestines (Sansom et al.,
2007). According to our siRNA experiments, miR-135b regula-
tion seemed to be independent from c-Myc activation; thus,
these two factors may control collateral transcriptional programsCancer Cell 25, 469–483, April 14, 2014 ª2014 Elsevier Inc. 479
Figure 7. MiR-135b Controls Tumor-Suppressor Genes
(A) Analysis of a cancer gene-associated panel in 460NCM cell transfected with pre-miR-135b or scrambled probes.
(B) APC (b), TGFbR2 (c), and DAPK1 (d) mRNA expression analyzed by RT-PCR following miR-135b overexpression (a).
(C) In silico target prediction for miR-135b binding sites in APC, TGFbR2, and DAPK1 30UTRs.
(D) Luciferase experiments for TGFbR2, DAPK1, and APC in NCM460 cells transfected with target-gene-Luc-WT or target-gene-Luc mutant, pre-miR-135b, or
scrambled miR.
(E) DAPK1 protein expression by WB following transfection with pre-miR-135b and specific siRNA.
(F) DAPK1 mRNA expression in dysplasia and cancer compared to normal adjacent tissues in IBD-associated CRC.
(G and H) TGFbR2 and p21 protein expression assessed following miR-135b overexpression and TGF-b stimulation (G). Apoptosis measured by caspase 3/7
assay following TGF-b stimulation (H).
(legend continued on next page)
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Figure 8. MiR-135b Is a Key Oncogenic Hub Mediating the Cancer
Phenotype Downstream of Genes Frequently Mutated in CRC
Schematic representation of genetic aberrations promoting miR-135b over-
expression and miR-135b downstream targets.
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proliferation was completely inhibited by miR-135b, some differ-
ences between the WT and the 135b-AMO mice were still
observed in term of total number of cells per crypt, suggesting
that other pathways independent from miR-135b regulation
may still be active upon miR-135b inhibition. A second potential
explanation to this observation may be technical in nature and
related to the ability to silence miR-135b completely by oligonu-
cleotides as compared to complete knockdown caused by Myc
deletion in Sansom’s model.
Compared to other downstream effectors of the Apc/b-cate-
nin pathway, such as cyclin D1, that are mostly involved in
tumor initiation rather than progression (Sansom et al., 2005),
miR-135b seems to retain its malignant potential in more
advanced carcinogenesis as suggested by the observation
that tumor growth was deeply affected by miR-135b silencing
in organoids harboring Apc, Pten, and p53 mutations. Our
data suggest that the progressive upregulation of miR-135b
in more advanced tumors may be caused by the convergence(I) TGFbR2 mRNA expression in dysplasia and cancer compared to normal adjac
(J) IL8 mRNA expression following miR-135b overexpression in NCM460 cells.
(K) Luciferase assay in NCM460 transfected with FIH-Luc-WT or FIH-gene-Luc m
30UTR is shown.
(L and M) FIH mRNA (L) and protein (M) expression following miR-135b overexp
(N) FIH, IL8, and VEGFA mRNA following siRNA transfection. *p < 0.05.
(O) Tube formation in HUVEC cells cultured with media from scrambled or miR-1
shown.
Bars represent the mean and SD of three experiments; p values are reported witof several pathways on miR-135b transcriptional regulation as
suggested by the analysis of miR-135b promoter activation.
Because miR-135b overexpression follows the kinetics of mu-
tations in CRC, it may represent a good biomarker of tumor
progression.
Crosstalk among different pathways is frequently observed in
colon carcinogenesis and may affect miR-135b expression at
different stages of disease and in different epithelial compart-
ments (progenitor versus mature cells). In IBD-associated can-
cers, for example, PI3K feeds positively on the Wnt pathway,
causing b-catenin phosphorylation and nuclear b-catenin accu-
mulation in progenitor epithelial cells (Lee et al., 2010). Thus,
PI3K mutations might have a feed-forward effect on miR-135b
expression in this setting. As previously shown (Nagel et al.,
2008), miR-135b in turn can control APC expression. The pres-
ence of this complex feedback loop (Figure 8) might explain
several in vivo observations. First, several pathways converging
on the same miR explain why no correlation has been previously
found between APCmutations and miR-135b expression (Nagel
et al., 2008). Second, the feedback loopmight be responsible for
the fine-tuning of miR-135b and the generation of a threshold ef-
fect on its target APC. IBD-associated CRCs are characterized
by rare mutations in the Wnt pathway (Aust et al., 2002) and
miR-135b overexpression. According to these observations,
we would expect most IBD cancers to show low APC expression
and nuclear b-catenin accumulation. On the contrary, only 30%–
50% of IBD-invasive tumors show nuclear b-catenin with little or
no accumulation in low- or high-grade dysplasia (Leedham et al.,
2009). Several reports (Valeri et al., 2010; Mukherji et al., 2011)
suggest the presence of a threshold effect in miR function. We
speculate that miR-135b deregulation might be responsible for
APC loss and b-catenin stabilization only in the fraction of IBD
tumors for which miR-135b expression has reached a defined
threshold.
MiR-based therapeutics represent a promising approach to
tailor cancer therapy; however, off-target effects may represent
amajor issue for thosemicroRNAs involved in physiological con-
ditions such asmiR-21 (Han et al., 2011). Contrary to other miRs,
miR-135b basal expression is very low in normal epithelium and
other organs as supported by the TCGA analysis. The low miR-
135b expression in normal epitheliummay be explained either by
the observation that, as observed for other Wnt targets (i.e., Lgr5
or Ascl2), a limited number of normal epithelial cells are under
Wnt control in physiological conditions or by the observation
that transcription factors such as FoxOs or USF1 may act as
brakes on miR-135b transcription in physiological conditions.
For these reasons, silencing miR-135b in CRC may represent a
promising targeted therapy characterized by high specificity
and limited toxicity.ent tissues in IBD-associated CRC.
utant vectors, pre-miR-135b, or scrambled miR. MiR-135b seed region in FIH
ression in 460NCM cells.
35b transfected cells: representative picture (left) and normalization (right) are
hin the figures. See also Table S8 and Figure S7.
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MiR and mRNA Expression Analysis
MiR expression profiling and mRNA expression of cancer-associated genes
were analyzed with nCounter from NanoString Technologies, using the
nCounter Mouse miRNA Expression assay kit and the nCounter Human
Cancer reference kit, respectively. The NanoString nCounter gene expression
system quantitates abundances of miRNAs and mRNA.
Technical normalization is performed using the synthetic positive controls to
adjust the counts for each miRNA target in that assay. Then biological normal-
ization is performed to correct for differences in sample abundances. Each
sample is normalized to the geometric mean of the top 50 most highly
expressed miRs. Student’s t test is used on normalized counts to calculate
statistical significances of pairwise comparisons. All of the calculations are
performed in R statistical computing and graphics environment (http://www.
r-project.org).
Animal Experiments and Tumor Induction
RNAs from CpC/Apc (matched tumor and normal), AOM/DSS (matched
cancer and normal), wild-type (untreated normal epithelium), and short-term
(3–5 days) DSS-treated mice (inflamed epithelium) for the initial miR expres-
sion screening were provided by Prof. Michael Karin (University of California
at San Diego). RNA from the intestinal epithelium of long-term (three cycles
[1 week each] over a 78 day period) DSS-treated mice was collected at Ohio
State University (OSU). All mice were C75BL/6 strain mice. For in vivo silencing
experiments, C57BL/6 mice were obtained from The Jackson Laboratory. All
mice were maintained in filter-topped cages on autoclaved food and water
at OSU according to National Institutes of Health guidelines, and all experi-
ments were performed in accordance with OSU and NIH guidelines and regu-
lations. CACwas induced as previously described (Grivennikov et al., 2009). All
experiments were approved by the Ethical Review Process of The University of
Glasgow. Experiments were carried out in compliance with UK Home Office
Animal (Scientific Procedures) Act 1986 and the EU Directive 2010.
Human Tissue Collection
Fresh-frozen and paraffin-embedded tissues from sporadic and IBD-related
CRCwerecollected following informedconsentandapproval of theethical com-
mitteesat (1) IstitutoScientificoRomagnoloper loStudioe laCuradei Tumori; (2)
OhioStateUniversityPathologyArchive; (3)Department ofPathology,University
of Ferrara; and (4) Department of Pathology, University of Padova.
ACCESSION NUMBERS
The Gene Expression Omnibus (GEO) accession numbers for miRNA and
mRNA expression data are GSE54177 (mouse tissue) and GSE54163 (human
cell lines).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and eight tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2014.03.006.
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